How much funding has FerroptoCure raised?

FerroptoCure has raised $6.5M in total funding, most recently a Series A round.

Who are FerroptoCure's investors?

FerroptoCure's investors include ANRI.

When was FerroptoCure founded?

FerroptoCure was founded in 2022.

Where is FerroptoCure headquartered?

FerroptoCure is headquartered in Tokyo, Japan.

What industry is FerroptoCure in?

FerroptoCure operates in Biotech, Healthcare.

How many employees does FerroptoCure have?

FerroptoCure has 1-10 employees.

FerroptoCure

Developing the world's first anticancer drug using ferroptosis

Tokyo, Japan · Founded 2022 · $6.5M raised

Biotech

Healthcare

Headquarters: Tokyo
Employees: 1–10
Founded: 2022
Business Model: B2B

Website: ferroptocure.com
Total Funding: $6.5M
Last Round: $6.5M Series ASep 2025
Rounds: 2

About

FerroptoCure Inc. is a Japanese clinical-stage biopharmaceutical company founded in May 2022, focused on developing the world's first anticancer drugs based on ferroptosis — a form of regulated cell death driven by iron-dependent lipid peroxidation. The company's novel mechanism targets the ferroptosis regulatory pathway to selectively kill cancer cells that are resistant to conventional therapies, addressing a significant unmet need in oncology. FerroptoCure has participated in global startup acceleration programs including the BioLabs LINK-BioBAY Masterclass and the CIC Global Startup Acceleration Program.

Summary

FerroptoCure is a Biotech company based in Tokyo, Japan, founded in 2022. It has raised $6.5M in total across 2 rounds, most recently a $6.5M Series A round in Sep 2025. Investors include ANRI.